ArticleCell death discovery2026
tRF-3005a regulates exon skipping of SPAG4 by interacting with RALY to drive gastric cancer progression.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Transfer RNA-derived fragments (tRFs) are emerging regulators in cancer, yet their role in the development and progression of gastric cancer (GC) remains unclear. Through RNA sequencing technology, this study identified a tRNA-derived fragment, tRF-3005a, that is significantly upregulated in GC tissues and cell lines and is associated with poor prognosis. Functionally, it promotes the proliferation, migration, and invasion of GC cells. Mechanistically, tRF-3005a bound to RALY, enhancing its interaction with SPAG4 mRNA, suppressing exon 8 skipping and leading to an increased generation of oncogenic SPAG4-L isoforms, thereby activating GRB14/PI3K/AKT signaling and ultimately promoting GC progression. This study reveals a novel mechanism wherein tRF-3005a promotes gastric cancer development by regulating RALY-mediated alternative splicing of SPAG4 to activate the GRB14/PI3K/AKT pathway, suggesting it may serve as a prognostic biomarker and therapeutic target.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.